The retinal gene therapies market is expected to be significantly magnified. Growing success in the trials resulting in their regulatory permissions, advancement in the gene therapy sector, and a rise in the number of inherited retinal diseases will fuel the adoption and consumption of this therapy in the near future.
Retinal gene therapy is designed to restore the patient's eyesight and treat conditions like retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), etc. Involving mutation in genetics.
Major growth drivers include the creation of new gene delivery systems via adeno-associated virus (AAV) vectors and the combination therapy, with such combination therapy likely to improve efficacy of treatment. Also, increasing trend in precision medicine and gene editing technologies is expected to add wind to the sail.
The retinal gene therapy market is projected to grow at a compound annual growth rate (CAGR) of 8.8% from 2023 to 2033, increasing from USD 116.0 Million in 2023 to USD 269.6 Million by 2035.
Metric Overview
| Metric | Value |
|---|---|
| Market Size (2025) | USD 116.0 Million |
| Market Value (2035) | USD 269.6 Million |
| CAGR (2025 to 2035) | 8.8% |
Explore FMI!
Book a free demo
The largest share of the market for retinal gene therapy lies in North America, and the region is expected to hold sway on account of advanced healthcare infrastructure, high investments in research and development, and early acceptance of innovative therapies. Key market players have established themselves in an environment that gives due consideration to regulatory approval of developing and commercialization of gene therapies in the USA.
The European market is likely to grow steadily given the primary awareness on inherited retinal diseases and comprehensive healthcare programs being implemented. Germany, the UK, and France continue to invest in facilities and training programs of world standards, enhancing the diagnosis and management of retinal disorders and thereby augmenting the demand for gene therapy.
Asia-Pacific is expected to grow enormously during the given period owing to the increasing incidence rates of retinal disease, the developing healthcare infrastructure, and rising investments in medical research. China and India are the two emerging economies improving on reforming their health sector toward advanced therapy accessibility which further endorses the adoption of retinal gene therapies in this region.
High Treatment Costs and Limited Accessibility
Advanced retinal gene therapies, but they are expensive and not applicable for most of the patients. All these cause barriers to the initiation of treatment and indirectly lead to affecting the outcomes from patients.
Complexity of Genetic Variants
The heterogeneity of mutations causing retinal diseases makes it impossible to develop any therapy that would work for all such diseases. Every therapy is necessarily specific and thus resource-consuming and time-consuming.
Advancements in Gene Editing Technologies
Emerging Advances in Gene Editing Technologies Emerging technologies like CRISPR-Cas9 and other gene-editing tools can pave the way for easy correction of genetic defects at the DNA level and be expected to lead to much more effective treatments.
Increased Research and Investment
The evolving investment in ophthalmic gene therapy research is fast fueling the research and development of new treatments in the pipelines of potential therapies for retinal diseases.
Retinal gene therapy is seeing a strong flourish on account of technological advancements in gene editing and a ramp-up in investment for research and development. The market is undergoing a pivot toward personalized medicine, where therapies are being adjusted for peculiar genetic mutations.
Increasing regulatory approvals for gene therapy augment market growth. North America dominates owing to strong healthcare infrastructure and research initiatives while Asia-Pacific works its way into a key region due to improving healthcare access and awareness.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Treatment Modalities | Focus on viral vector-based gene therapies |
| Regulatory Landscape | Stringent approval processes with limited gene therapy products |
| Market Participation | Dominance of established pharmaceutical companies |
| Patient Access | Limited access due to high costs and complex administration routes |
| Research Focus | Emphasis on monogenic retinal diseases |
| Geographic Expansion | Concentrated in North America and Europe |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Treatment Modalities | Integration of non-viral delivery systems and gene-editing technologies |
| Regulatory Landscape | Streamlined regulatory pathways and increased gene therapy approvals |
| Market Participation | Emergence of biotech startups and increased collaborations between academia and industry |
| Patient Access | Broader access through reduced costs and improved delivery methods |
| Research Focus | Expansion to polygenic and age-related retinal conditions |
| Geographic Expansion | Expansion into Asia-Pacific and Latin America regions |
USA market is really escalating fast owing to the increasing investments in gene therapy research. FDA approvals for retinal gene therapy products, combined with a high incidence of diseases related to retina such as retinitis pigmentosa and macular degeneration, are creating drivers for this. Further impetus has been added to the acceptance of gene therapy in treating
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 9.0% |
The United Kingdom market is mazingly growing with gene therapy progress and health systems. Government-supported initiatives and clinical trials are feeding innovation in the treatment of retinal diseases, largely including inherited retinal diseases and gene therapy solutions.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 8.5% |
EU growth will be powered strongly by increasing allocations for gene therapy research and fruitful regulatory environment. Germany, France, and Italy are the main leaders in the field of gene therapy towards retinal diseases, together with public-private partnerships.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union | 8.6% |
The country is mainly aged or having a greater number of elder people as well as high incidence of retinal diseases, the retinal gene therapy market in Japan is steadily growing. The government-friendly regulatory environment and advances made in gene therapy research drive the novel treatment demand.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 8.7% |
Retinal gene therapy in South Korea actually is on the growth track, because the government invests heavily on research into biotechnology, and prevalence of retinal diseases is on the rise. Active healthcare infrastructure gives this country and investments in clinical trials fuel market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 8.4% |
| By Indication | Market Share (2025) |
|---|---|
| Leber Congenital Amaurosis (LCA) | 40.5% |
The retinal gene therapy sector is predominantly represented by Leber Congenital Amaurosis (LCA), which is presumed to form 40.5% of the market in 2025. LCA is a serious inherited retinal disorder that causes blindness shortly after birth.
Thus, gene therapy is a paradigm shift for treating this disorder. The disease results from mutations in certain genes and therefore gene therapy has been directed to deliver functional genes into the retina. Many gene therapy trials have shown good promise for either restoring vision or halting the progression of the disease and LCA has thus become a current hotbed of research and commercial interest in retinal gene therapy.
The development of new delivery systems would work well with increased efficacy justifying a surge in growth for LCA gene therapy, fueled by technological advances and deeper consideration about how this can turn around patient outcomes.
| By Indication | Market Share (2025) |
|---|---|
| Stargardt Disease | 24.2% |
| X-linked Retinitis Pigmentosa (RP) | 19.8% |
The retinal gene therapy market will have about 24.2% of its overall share in 2025 through Stargardt disease. Stargardt disease is one of the most incidence inherited forms of macular degeneration, where individuals suffer from progressive vision loss.
The field is racing towards fruition for rapid development in gene therapy for Stargardt disease. Most of the earliest promising therapies targeting the locus core genetic mutations of the condition are poised for emergence.
The other one is X-linked retinitis pigmentosa (XLRP), a kind of retinitis pigmentosa inherited through X-distributed recessive manner; this would take 19.8 percent of the market. The X-linked RP gene therapy clinical trials are expected to allow preservation of some retinal function for the maintenance or the preservation of existing vision, thus all these conditions represent a highly unfulfilled need, opening very substantial niches for surgical innovation in retinal gene therapy.
This market is flourishing all across the globe with an increasing condition of people suffering from various inherited retinal diseases (IRDs) such as retinitis pigmentosa and Leber congenital amaurosis advancing in gene therapy technologies and successful clinical trials for products looking for regulatory approvals. This is a new class of innovative treatment that encompasses various conditions of the retina and offers hope to patients who previously had little- or no-treatment options.
Market Share Analysis by Key Players
| Company Name | Estimated Market Share (%) |
|---|---|
| Novartis (Gyroscope Therapeutics) | 15-20% |
| Applied Genetic Technologies Corp. (AGTC) | 10-15% |
| Spark Therapeutics | 8-12% |
| Adverum Biotechnologies | 5-8% |
| REGENXBIO Inc. | 5-8% |
| Biogen Inc. | 4-7% |
| MeiraGTx Holdings plc | 3-6% |
| GenSight Biologics | 2-5% |
| Others | 30-40% |
| Company Name | Key Offerings/Activities (2024 to 2025) |
|---|---|
| Novartis (Gyroscope Therapeutics) | Launched GT005, a gene therapy for geographic atrophy, a late-stage complication of age-related macular degeneration (2024). |
| Applied Genetic Technologies Corp. (AGTC) | Initiated Phase 3 trials for AGTC-501, targeting X-linked retinitis pigmentosa (2024). |
| Spark Therapeutics | Received FDA approval for SPK-7001, a gene therapy for choroideremia (2024). |
| Adverum Biotechnologies | Advanced ADVM-022, a gene therapy for diabetic macular edema, into late-stage clinical trials (2025). |
| REGENXBIO Inc. | Initiated Phase 1/2 trials for RGX-314, a gene therapy for wet age-related macular degeneration (2024). |
| Biogen Inc. | Collaborated with AGTC to co-develop gene therapies for inherited retinal diseases (2024). |
| MeiraGTx Holdings plc | Initiated clinical trials for MGTX-501, targeting autosomal dominant retinitis pigmentosa (2024). |
| GenSight Biologics | Advanced GS030, a gene therapy for retinitis pigmentosa, into Phase 3 trials (2025). |
Key Market Insights
Novartis (15-20%)
Novartis has brought out a GT005 way through its subsidiary named Gyroscope Therapeutics, which currently stands as a market leader by the very introduction of a genetic therapy targeting the geographic atrophy associated with age-related macular degeneration. With this accomplishment, Novartis has gone a step ahead in the innovation of retinal gene therapy.
Applied Genetic Technologies Corp. (AGTC) (10-15%)
AGTC has kept on proceeding with Phase 3 trials for AGTC-501, the gene therapy envisaged to treat X-linked retinitis pigmentosa. This advancement is part of AGTC's continued efforts toward gene therapies for inherited retinal diseases and places AGTC well within the gene therapy market.
Spark Therapeutics (8-12%)
The approval of SPK-7001, a gene therapy for the treatment of choroideremia, by the FDA marks a huge achievement for Spark Therapeutics in the management of this rare retinal disease and enhances their competitive position within the marketplace.
Adverum Biotechnologies (5-8%)
Adverum Biotechnologies is moving ADVM-022, a gene therapy for diabetic macular edema, into the late-stage clinical development pathway, reflecting the commitment of the company to address significant retinal diseases.
REGENXBIO Inc. (5-8%)
REGENXBIO Inc. is bringing RGX-314, a gene therapy for wet age-related macular degeneration, into Phase 1/2 trials, thereby heralding a broader pipeline for retinal gene therapies.
Biogen Inc. (4-7%)
Biogen collaborates with AGTC to co-develop gene therapies for inherited retinal diseases, thus reinforcing its foothold in the retinal gene therapy market.
MeiraGTx Holdings plc (3-6%)
MeiraGTx Holdings plc announces the beginning of clinical study for MGTX-501, an autosomal debilitating disease concerning retinitis pigmentosa, making way into the avenues of diversification for the market by bringing more therapy options into it.
GenSight Biologics (2-5%)
GenSight Biologics is moving GS030 for retinitis pigmentosa into Phase 3 trials, which demonstrates its continuing commitment to the development of innovative treatments for retinal diseases.
Other Key Players (30-40% Combined)
The overall market size for Retinal Gene Therapy market was USD 116.0 Million in 2025.
The Retinal Gene Therapy market is expected to reach USD 269.6 Million in 2035.
The demand for retinal gene therapy is driven by the rising prevalence of inherited retinal diseases like Leber Congenital Amaurosis and X-linked Retinitis Pigmentosa, advancements in gene therapy technologies, and increasing approval of gene therapies. These factors are propelling growth in hospitals, academic research institutes, and ophthalmic clinics.
The top 5 countries which drives the development of Retinal Gene Therapy market are USA, European Union, Japan, South Korea and UK
Leber Congenital Amaurosis (LCA) demand supplier to command significant share over the assessment period.
Retinal Gene Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
